Program
Insulin, Regular, Human
Also written as “Technosphere Insulin”, “inhaled human insulin” and “Human Insulin Inhalation Powder”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1 · Diabetes Mellitus · Asthma · Diabetes, Gestational, led by 13 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Mannkind | 261 open or running | phase 4since Apr 16, 2021 | Mar 27, 2006 | Mar 2027phase 2 · NCT07224321 |
| Novo Nordisk | 190 open or running | phase 4since Aug 10, 2006 | Jul 17, 2003 | none ahead |
| Eli Lilly | 100 open or running | phase 4since Jan 22, 2013 | Aug 4, 2005 | none ahead |
| Biodel | 50 open or running | phase 3since Oct 5, 2007 | Oct 5, 2007 | none ahead |
| Pfizer | 40 open or running | phase 3since Feb 2, 2006 | Feb 2, 2006 | none ahead |
| Dance Biopharm | 30 open or running | phase 2since Mar 9, 2016 | Mar 9, 2016 | none ahead |
| Halozyme Therapeutics | 30 open or running | phase 2since Oct 15, 2008 | Jun 24, 2008 | none ahead |
| Sanofi | 30 open or running | phase 4since Jun 26, 2012 | Sep 2, 2010 | none ahead |
| Transdermal Delivery Solutions | 21 open or running | phase 3since Dec 1, 2021 | Apr 21, 2021 | Oct 15, 2027phase 3 · NCT05159453 |
| diabetes-and-glandular-disease-clinic | 10 open or running | phase 4since Oct 9, 2019 | Oct 9, 2019 | none ahead |
| ikfe-cro-gmbh | 10 open or running | phase 4since Dec 5, 2011 | Dec 5, 2011 | none ahead |
| informed-data-systems-inc | 10 open or running | phase 4since Oct 10, 2017 | Oct 10, 2017 | none ahead |
| The United Laboratories International | 10 open or running | phase 1since May 5, 2026 | May 5, 2026 | none ahead |
Also a collaborator on its studies: langford-research-institute-inc, Insulet, DexCom, Profil Institut für Stoffwechselforschung, Alkermes, wcct-global and Nektar Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Dec 11, 2006.
- Sep 23, 2015Phase 3 study in Diabetes Mellitus, Type 2Eli Lilly · NCT02561078 · 420 enrolled · United States, Puerto Rico
- Mar 9, 2016Dance Biopharm's first study: phase 2 study in Diabetes Mellitus, Type 2New to Dance BiopharmDance Biopharm · NCT02716610 · 24 enrolled
- Oct 2, 2017Phase 2 study in AsthmaDance Biopharm · NCT03307512 · 40 enrolled · United States
- Oct 10, 2017informed-data-systems-inc's first study: phase 4 study in Diabetes Mellitus, Type 2New to informed-data-systems-incinformed-data-systems-inc · NCT03313960 · 400 enrolled · United States
- Feb 25, 2019Phase 2 study in Diabetes Mellitus, Type 2Dance Biopharm · NCT04100473 · 24 enrolled · Germany
- Oct 9, 2019diabetes-and-glandular-disease-clinic's first study: phase 4 study in Type 2 Diabetes Treated With InsulinNew to diabetes-and-glandular-disease-clinicdiabetes-and-glandular-disease-clinic · NCT04125082 · 29 enrolled · United States
- Apr 16, 2021Phase 4 study in Diabetes Mellitus, Type 1Mannkind · NCT04849845 · 20 enrolled · United States
- Apr 21, 2021Transdermal Delivery Solutions's first study: early phase 1 study in Pharmacodynamic Response to Small Doses of InsulinNew to Transdermal Delivery SolutionsTransdermal Delivery Solutions · NCT04857320 · 7 enrolled · United States
- Jun 22, 2021Phase 3 study in Diabetes Mellitus, Type 1Mannkind · NCT04974528 · 319 enrolled · United States
- Dec 1, 2021Phase 3 study in Glucose, High BloodTransdermal Delivery Solutions · NCT05159453 · 30 planned · United States
- Feb 7, 2022Phase 4 study in Diabetes Mellitus, Type 1Mannkind · NCT05243628 · 33 enrolled · United States
- Jun 2, 2023Phase 4 study in Diabetes Mellitus, Type 1Mannkind · NCT05904743 · 141 enrolled · United States
- Oct 31, 2025Phase 2 study in Diabetes Mellitus, Type 1Mannkind · NCT07224321 · 100 planned · United States
- May 5, 2026The United Laboratories International's first study: phase 1 study in Pharmacokinetics and PharmacodynamicsNew to The United Laboratories InternationalThe United Laboratories International · NCT07608692 · 32 enrolled · China
Ahead
- Mar 2027Primary completion: phase 2 study in Diabetes Mellitus, Type 1Mannkind · NCT07224321
- Oct 15, 2027Primary completion: phase 3 study in Glucose, High BloodTransdermal Delivery Solutions · NCT05159453
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
The newest 60 of 79 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07608692Pharmacokinetics and Pharmacodynamics · China | 1 | Completed | The United Laboratories International | Nov 25, 2025 | 32 |
| NCT07224321Diabetes Mellitus, Type 1 · United States | 2 | Recruiting | Mannkind | Mar 2027 | 100 |
| NCT05904743Diabetes Mellitus, Type 1 · United States | 4 | Completed | Mannkind | Mar 26, 2024 | 141 |
| NCT05243628Diabetes Mellitus, Type 1 · United States | 4 | Completed | Mannkind | Oct 17, 2022 | 33 |
| NCT05159453Glucose, High Blood · United States | 3 | Not yet recruiting | Transdermal Delivery Solutions | Oct 15, 2027 | 30 |
| NCT04974528Diabetes Mellitus, Type 1 · United States | 3 | Completed | Mannkind | Oct 3, 2024 | 319 |
| NCT04857320Pharmacodynamic Response to Small Doses of Insulin · United States | Early 1 | Completed | Transdermal Delivery Solutions | Nov 15, 2021 | 7 |
| NCT04849845Diabetes Mellitus, Type 1 · United States | 4 | Completed | Mannkind | May 28, 2021 | 20 |
| NCT04125082Type 2 Diabetes Treated With Insulin · United States | 4 | UNKNOWN | diabetes-and-glandular-disease-clinic | Mar 15, 2020 | 29 |
| NCT04100473Diabetes Mellitus, Type 2 · Germany | 2 | Completed | Dance Biopharm | Aug 11, 2018 | 24 |
| NCT03313960Diabetes Mellitus, Type 2 · United States | 4 | UNKNOWN | informed-data-systems-inc | Sep 30, 2018 | 400 |
| NCT03307512Asthma · United States | 2 | Terminated | Dance Biopharm | Jul 30, 2019 | 40 |
| NCT02716610Diabetes Mellitus, Type 2 | 2 | Completed | Dance Biopharm | Jan 2014 | 24 |
| NCT02561078Diabetes Mellitus, Type 2 · United States, Puerto Rico | 3 | Completed | Eli Lilly | May 9, 2017 | 420 |
| NCT02527265Diabetes Mellitus, Type 1 · United States | 2 | Completed | Mannkind | Mar 17, 2020 | 30 |
| NCT02485327Diabetes Mellitus, Type 1 · Germany | 1 | Completed | Mannkind | Nov 2015 | 22 |
| NCT01774968Diabetes Mellitus, Type 2 · United States, Puerto Rico | 4 | Completed | Eli Lilly | May 2014 | 325 |
| NCT01630369Diabetes Mellitus, Type 2 · Ukraine | 4 | Completed | Sanofi | May 2013 | 552 |
| NCT01544881Diabetes Mellitus, Type 1 · United States | 1 | Completed | Mannkind | Sep 2012 | 17 |
| NCT01500850Diabetes Mellitus, Type 2 · Germany | 4 | UNKNOWN | ikfe-cro-gmbh | Oct 2012 | 60 |
| NCT01451398Diabetes Mellitus, Type 2 · United States, Brazil, Russian Federation and more | 3 | Completed | Mannkind | Jun 2013 | 353 |
| NCT01448070Diabetes Mellitus · United Kingdom | 1 | Completed | Novo Nordisk | Dec 20, 2002 | 28 |
| NCT01365117Healthy Volunteers · United States | 1 | Completed | Mannkind | Feb 2011 | 50 |
| NCT01353469Diabetes Mellitus, Type 2 · China | 3 | Completed | Sanofi | Nov 2012 | 485 |
| NCT01269606Diabetes Mellitus · Japan | 1 | Completed | Novo Nordisk | Mar 2011 | 13 |
| NCT01194882Diabetes Mellitus, Type 1 · Belgium, France, Netherlands and more | 3 | Completed | Sanofi | Feb 1, 2018 | 479 |
| NCT01000922Diabetes Mellitus · United States | 2 | Completed | Biodel | Jan 2008 | 24 |
| NCT00934414Diabetes Mellitus, Type 2 · United States | 2 | Completed | Mannkind | Aug 2006 | 24 |
| NCT00916357Diabetes Mellitus, Type 2 · United States | 2 | Completed | Halozyme Therapeutics | Nov 2009 | 23 |
| NCT00875459Diabetes Mellitus | 3 | Completed | Biodel | Feb 2010 | 233 |
| NCT00875108Diabetes Mellitus | 3 | Completed | Biodel | Jan 2010 | 116 |
| NCT00774800Diabetes Mellitus, Type 1 · United States | 2 | Completed | Halozyme Therapeutics | Mar 2009 | 22 |
| NCT00725036Diabetes Mellitus · Australia | 3 | Completed | Novo Nordisk | Dec 14, 2004 | 305 |
| NCT00705536Diabetes Mellitus · United States | 1 | Completed | Halozyme Therapeutics | Feb 2008 | 26 |
| NCT00700622Diabetes Mellitus, Type 1 · United States, Brazil | 3 | Terminated | Mannkind | Nov 2009 | 130 |
| NCT00676819Diabetes Mellitus · Germany | 4 | Completed | Novo Nordisk | Jul 19, 2002 | 19 |
| NCT00662857Diabetes Mellitus, Type 1 · United States | 2 | Completed | Mannkind | Nov 2008 | 29 |
| NCT00642616Diabetes Mellitus, Type 1 · United States, Russian Federation, Ukraine | 3 | Terminated | Mannkind | Nov 2014 | 34 |
| NCT00617565Diabetes Mellitus · China | 3 | Completed | Novo Nordisk | Nov 26, 2003 | 219 |
| NCT00570687Diabetes Mellitus, Type 2 · Germany | 2 | Completed | Mannkind | Jan 2009 | 30 |
| NCT00569400Diabetes Mellitus · Australia, Hong Kong, Malaysia and more | 3 | Completed | Novo Nordisk | Jan 19, 2004 | 241 |
| NCT00567775Diabetes Mellitus · Denmark | 2 | Completed | Novo Nordisk | Nov 20, 2002 | 27 |
| NCT00542633Diabetes Mellitus, Type 2 | 3 | Completed | Biodel | Aug 2008 | 472 |
| NCT00542724Diabetes Mellitus, Type 1 | 3 | Completed | Biodel | Jul 2008 | 462 |
| NCT00539890Diabetes Mellitus, Type 2 · Russian Federation | 3 | Completed | Mannkind | 0 | |
| NCT00539396Diabetes Mellitus, Type 1 | 2 | Completed | Mannkind | 110 | |
| NCT00523042Diabetes Mellitus · United States, Australia, Former Serbia and Montenegro and more | 3 | Terminated | Novo Nordisk | Feb 28, 2008 | 10 |
| NCT00511979Healthy | 1 | Completed | Mannkind | Feb 2000 | 12 |
| NCT00511732Diabetes Mellitus, Type 2 | 2 | Completed | Mannkind | Aug 2005 | 227 |
| NCT00511719Diabetes Mellitus, Type 2 | 2 | Completed | Mannkind | Apr 2004 | 13 |
| NCT00511602Diabetes Mellitus, Type 2 | 2 | Completed | Mannkind | Nov 2004 | 123 |
| NCT00490854Diabetes Mellitus, Type 2 · Japan | 3 | Completed | Eli Lilly | May 2008 | 129 |
| NCT00476437Diabetes Mellitus · Japan | 3 | Completed | Novo Nordisk | Nov 2007 | 81 |
| NCT00472953Diabetes Mellitus · Argentina, India, Romania and more | 3 | Terminated | Novo Nordisk | Mar 5, 2008 | 38 |
| NCT00469586Diabetes Mellitus · Argentina, Austria, Belgium and more | 3 | Terminated | Novo Nordisk | Apr 24, 2008 | 174 |
| NCT00427154Diabetes Mellitus · United States | 3 | Terminated | Novo Nordisk | Mar 11, 2008 | 227 |
| NCT00424437Diabetes Mellitus, Type 1 · United States, Canada | 3 | Completed | Pfizer | 320 | |
| NCT00424333Diabetes Mellitus, Type 1 · United States, Canada | 3 | Completed | Pfizer | 320 | |
| NCT00419718Diabetes Mellitus · Austria | 1 | Completed | Novo Nordisk | Nov 2005 | 23 |
| NCT00410033Diabetes Mellitus · Sweden | – | Completed | Novo Nordisk | May 2006 | 74 |
How it is read
Names in the registry
- “Technosphere Insulin”, 13 entries
- “inhaled human insulin”, 12 entries
- “Human Insulin Inhalation Powder”, 7 entries
- “human insulin”, 7 entries
- “Technosphere® Insulin Inhalation Powder”, 5 entries
Codes read as this program: INH69, INH139, INH208, HR1799.
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 33 studies
- Diabetes Mellitus, Type 1, 29 studies
- Diabetes Mellitus, 10 studies
- Asthma, 1 study
- Diabetes, Gestational, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.